Literature DB >> 19523353

Overview of evaluation and treatment guidelines for epilepsy.

John M Stern1.   

Abstract

Choosing the most appropriate treatment for a patient with epilepsy depends on complicated and critical decisions. The number of treatment options has become large, and evidence of effectiveness for each treatment continues to expand. To address this problem, numerous guidelines have been produced by several societies and organizations. However, the guidelines do not always agree in their recommendations, mostly because of differing methods reflecting distinct purposes, but these differences are useful because they highlight both what is incontrovertible and what is unknown. Overall, the evidence needed to choose an antiepileptic drug (AED) wisely is incomplete, and no individual AED or group of AEDs is universally preferred as first-line therapy. Initial treatment should be based in part on the seizure-type diagnosis because the AEDs differ in their efficacy for various seizure types. The AEDs also differ in their safety, tolerability, and potential for pharmacologic interactions. These issues and the patient's general medical history are additional factors to be used when selecting an AED. The failure of AEDs to completely control seizures should lead to consideration of epilepsy surgery, especially for patients with mesial temporal lobe epilepsy. However, there is no consensus regarding how many AEDs should be tried before the condition is deemed pharmacoresistant. Vagus nerve stimulation and the ketogenic diet are alternative treatments for patients with pharmacoresistant epilepsy who do not have epilepsy surgery or who have unsuccessful surgery.

Entities:  

Year:  2009        PMID: 19523353     DOI: 10.1007/s11940-009-0031-7

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  34 in total

Review 1.  The use of diet in the treatment of epilepsy.

Authors:  Elizabeth E Bailey; Heidi H Pfeifer; Elizabeth A Thiele
Journal:  Epilepsy Behav       Date:  2005-02       Impact factor: 2.937

2.  Practice parameter: management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors: 
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

Review 3.  Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  J J Riviello; S Ashwal; D Hirtz; T Glauser; K Ballaban-Gil; K Kelley; L D Morton; S Phillips; E Sloan; S Shinnar
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

4.  Anticonvulsant effect of anterior thalamic high frequency electrical stimulation in the rat.

Authors:  M A Mirski; L A Rossell; J B Terry; R S Fisher
Journal:  Epilepsy Res       Date:  1997-09       Impact factor: 3.045

Review 5.  Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Authors:  J A French; A M Kanner; J Bautista; B Abou-Khalil; T Browne; C L Harden; W H Theodore; C Bazil; J Stern; S C Schachter; D Bergen; D Hirtz; G D Montouris; M Nespeca; B Gidal; W J Marks; W R Turk; J H Fischer; B Bourgeois; A Wilner; R E Faught; R C Sachdeo; A Beydoun; T A Glauser
Journal:  Neurology       Date:  2004-04-27       Impact factor: 9.910

Review 6.  Menopause and bone density issues for women with epilepsy.

Authors:  Cynthia L Harden
Journal:  Neurology       Date:  2003-09-01       Impact factor: 9.910

Review 7.  Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.

Authors:  C L Harden; P B Pennell; B S Koppel; C A Hovinga; B Gidal; K J Meador; J Hopp; T Y Ting; W A Hauser; D Thurman; P W Kaplan; J N Robinson; J A French; S Wiebe; A N Wilner; B Vazquez; L Holmes; A Krumholz; R Finnell; P O Shafer; C Le Guen
Journal:  Neurology       Date:  2009-04-27       Impact factor: 9.910

8.  Reassessment: neuroimaging in the emergency patient presenting with seizure (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  C L Harden; J S Huff; T H Schwartz; R M Dubinsky; R D Zimmerman; S Weinstein; J C Foltin; W H Theodore
Journal:  Neurology       Date:  2007-10-30       Impact factor: 9.910

Review 9.  Epilepsy and bone health in adults.

Authors:  Alison M Pack; Martha J Morrell
Journal:  Epilepsy Behav       Date:  2004-02       Impact factor: 2.937

Review 10.  Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.

Authors:  M T Mackay; S K Weiss; T Adams-Webber; S Ashwal; D Stephens; K Ballaban-Gill; T Z Baram; M Duchowny; D Hirtz; J M Pellock; W D Shields; S Shinnar; E Wyllie; O C Snead
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

View more
  3 in total

Review 1.  Disease modification in epilepsy: from animal models to clinical applications.

Authors:  Melissa L Barker-Haliski; Dan Friedman; Jacqueline A French; H Steve White
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

2.  Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships.

Authors:  Philippa Delahoy; Sally Thompson; Ian C Marschner
Journal:  BMC Neurol       Date:  2010-11-01       Impact factor: 2.474

3.  The adolescent or adult with generalized tonic-clonic seizures.

Authors:  Roop Gursahani; Namit Gupta
Journal:  Ann Indian Acad Neurol       Date:  2012-04       Impact factor: 1.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.